← Leaderboards
Lindsey Ingerman James
Univ Of North Carolina Chapel Hill
$6,093,406
Attributed
$6,093,406
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,093,406 · 3
By mechanism
R61$2,672,850 · 1
R33$1,756,996 · 1
R01$1,663,560 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Brian D Strahl$12,633,933
- Sundeep Kalantry$10,177,211
- Samantha Tulenko$179,695
- Ian J Davis$7,130,869
- Edward P Browne$7,453,313
Others in their field
Other Emerging Leaders on “Biology”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$377,088,269
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$343,713,561
- Chanza Baytop · Westat, Inc.$271,217,917
- Lynn Briscoe · Leidos Biomedical Research, Inc.$149,803,496
Research focus
BiologyEpigenetic ProcessSamplingComplexMediatingKnock-DownGene SilencingLigandsEpigenetic RegulationSmall Molecule InhibitorProteinsMemberGenetic TranscriptionProtein DegradationGeneticEpigenetic TherapyEpigenomeCellular AssayCellsAcute Lymphoblastic Leukemia CellFamilyBindingCell LineDrug Discovery
Grant awards (11)
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY$138,700
R01 · FY2024 · CA · contact PI
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL$878,498
R33 · FY2023 · DA · contact PI
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY$327,284
R01 · FY2023 · CA · contact PI
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL$878,498
R33 · FY2022 · DA · contact PI
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY$327,458
R01 · FY2022 · CA · contact PI
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY$188,310
R01 · FY2021 · CA · contact PI
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL$890,017
R61 · FY2020 · DA · contact PI
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY$334,476
R01 · FY2020 · CA · contact PI
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL$890,017
R61 · FY2019 · DA · contact PI
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY$347,332
R01 · FY2019 · CA · contact PI
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL$892,816
R61 · FY2018 · DA · contact PI